BIXT on OTC
BIOXYTRAN, INC
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with Clene Inc., NOMAD POWER SOLUTIONS, INC. or Anixa Biosciences Inc, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
Every line of the income statement in the latest annual report, as filed.8
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Research and development | $454.0K | $112.3K |
| General and administrative | $648.2K | $1.2M |
| General and administrative affiliates | $740.3K | $943.2K |
| Total operating expenses | $1.8M | $2.2M |
| Loss from operations | -$1.8M | -$2.2M |
| Loss of issuance | $488.3K | |
| Change in FV of Derivative | -$216.7K | $133.1K |
| Interest expense | -$134.3K | -$84.2K |
| Interest expense affiliate | -$51.9K | -$8.3K |
| Amortization of Intellectual Property | -$11.5K | -$8.0K |
| Debt forgiveness | $133.9K | |
| Debt discount amortization | -$677.8K | |
| Total other expenses | -$280.6K | -$156.9K |
| Net loss before provision for income taxes | -$2.1M | -$2.4M |
| Net loss | -$2.1M | -$2.4M |
| Net loss attributable to the non-controlling interest | $13.3K | |
| NET LOSS ATTRIBUTABLE TO BIOXYTRAN | -$2.1M | -$2.4M |
| Loss per common share, basic | -$0.02 | -$0.02 |
| Loss per common share, diluted | -$0.02 | -$0.02 |
| Weighted average number of common shares outstanding, basic | 91.8M shares | 138.6M shares |
| Weighted average number of common shares outstanding, diluted | 91.8M shares | 138.6M shares |
Every line of the balance sheet in the latest annual report, as filed.8
| Period ending | 2025-12-31 | 2024-12-31 | 2024-10-31 |
|---|---|---|---|
| Cash | $509.9K | $5.2K | |
| Pre-payment | $3.6K | ||
| Total current assets | $513.5K | $5.2K | |
| Intangibles, net | $145.1K | $133.5K | |
| Total assets | $658.6K | $138.7K | |
| Accounts payable and accrued expenses | $849.6K | $278.3K | |
| Other short-term loans | $50.0K | $48.0K | |
| Derivative Liability | $403.4K | $186.7K | |
| Convertible notes payable, net of premium and discount | $805.0K | $805.0K | |
| Total current liabilities | $3.2M | $1.9M | |
| Total liabilities | $3.2M | $1.9M | |
| Preferred stock, $0.001 par value; 50,000,000 shares authorized, 43,283,991 and 43,158,248 issued and outstanding as at December 31, 2025, and 2024, respectively | $43.3K | $43.2K | |
| Common stock, $0.001 par value; 400,000,000 shares authorized; 108,147,731 and 86,782,908 issued and outstanding as at December 31, 2025, and 2024, respectively | $108.1K | $86.8K | |
| Additional paid-in capital | $18.3M | $17.0M | |
| Accumulated deficit | -$21.0M | -$18.9M | |
| Total stockholders deficit | -$2.6M | -$1.8M | |
| Total liabilities and stockholders equity | $658.6K | $138.7K | |
| Preferred stock, par value | $0.00 | $0.00 | $0.43 |
| Preferred stock, shares authorized | 50.0M shares | 50.0M shares | 28.5M shares |
| Preferred stock, shares issued | 43.3M shares | 43.2M shares | |
| Preferred stock, shares outstanding | 43.3M shares | 43.2M shares | |
| Common stock, par value | $0.00 | $0.00 | $0.09 |
| Common stock, shares authorized | 400.0M shares | 400.0M shares | 3.4M shares |
| Common stock, shares issued | 108.1M shares | 86.8M shares | |
| Common stock, shares outstanding | 108.1M shares | 86.8M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.8
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$2.1M | -$2.4M |
| Debt discount amortization, incl. issuance of warrants | $677.8K | |
| Amortization of IP | $11.5K | $8.0K |
| Stock-based compensation | $170.4K | $199.7K |
| Stock-based compensation affiliates | $207.3K | $238.6K |
| Interest paid for note conversion | $164.4K | |
| Gain/Loss of Issuance | -$253.0K | |
| Acquisition of subsidiary | $368.6K | |
| Acquisition of subsidiary, affiliates | -$378.9K | |
| Change in FV of Derivative | $216.7K | -$133.1K |
| Debt forgivness | -$133.9K | |
| Pre-payments | -$3.6K | |
| Accounts payable and accrued expenses | $495.9K | $258.2K |
| Accounts payable and accrued expenses affiliates | $632.2K | $848.5K |
| Net cash used in operating activities | -$526.5K | -$381.3K |
| Investment in intangibles | -$23.1K | -$28.2K |
| Net cash used in investing activities | -$23.1K | -$28.2K |
| Proceeds from stock sales | $439.0K | $63.0K |
| Proceeds from note sales | $61.5K | |
| Short-term loans | $12.0K | $48.0K |
| Warrant issued | $292.2K | |
| Short-term loans from affiliates | $311.1K | $216.1K |
| Net cash provided by financing activities | $1.1M | $388.6K |
| Net increase (decrease) in cash | $504.8K | -$20.9K |
| Interest paid | $164.4K | |
| Common shares issued for the conversion of principal and accrued interest | $1.4M | |
| Debt discount on convertible note | $105.0K | |
| Forfeiture of warrants | $21.6K | |
| Reclassification from affiliate loans to affiliate accounts payable | $39.0K | |
| Reclassification from affiliate loans to other short-term liabilities | $10.0K | |
| Issuance, debt conversion affiliates | $1.1M | |
| Issuance, debt conversion | $657.2K | |
| Payroll forgiveness affiliates | $214.8K | |
| Gain/Loss of issuance | $488.3K |
Former names
Recent filings
- Aug 14, 202610-Q
- Aug 11, 20268-K
- May 15, 202610-Q
- Apr 15, 202610-K
- Apr 1, 2026NT 10-K
- Mar 20, 20268-K
- Mar 13, 20268-K
- Mar 2, 20268-K
- Feb 17, 20268-K
- Feb 11, 20268-K
- Jan 5, 20268-K
- Dec 15, 20258-K
- Nov 18, 20254/A PRIMARY DOCUMENT
- Nov 18, 20254/A PRIMARY DOCUMENT
- Nov 18, 20254/A PRIMARY DOCUMENT
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARBIOXYTRAN, INC filings on SEC EDGAR
- 2SEC EDGARBIOXYTRAN, INC filings on SEC EDGAR
- 3SEC EDGARBIOXYTRAN, INC 10-K for fiscal 2019
- 4SEC EDGARBIOXYTRAN, INC 10-K for fiscal 2020
- 5SEC EDGARBIOXYTRAN, INC 10-K for fiscal 2021
- 6SEC EDGARBIOXYTRAN, INC 10-K for fiscal 2022
- 7SEC EDGARBIOXYTRAN, INC 10-K for fiscal 2023
- 8SEC EDGARBIOXYTRAN, INC 10-K for fiscal 2024
- 9SEC EDGARBIOXYTRAN, INC 10-Q for fiscal 2026
- 10SEC EDGARBIOXYTRAN, INC 10-Q for fiscal 2026